(Q60536516)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212398%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

editorial

0 references

title

Targeting glutamate to treat schizophrenia: lessons from recent clinical studies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212398%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212398%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

author name string

Oliver D Howes

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212398%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

Daniel C Javitt

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212398%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

publication date

23 May 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212398%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

number of pages

4

1 reference

inferred from page(s)

published in

Psychopharmacology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212398%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

volume

233

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212398%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

issue

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212398%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

page(s)

2425-2428

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212398%20AND%20SRC:MED&resulttype=core&format=json

Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia

2 April 2020

cites work

1 reference

12 December 2020

The practical management of refractory schizophrenia--the Maudsley Treatment REview and Assessment Team service approach.

1 reference

12 December 2020

Perspectives on the mGluR2/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?

1 reference

12 December 2020

Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers

1 reference

12 December 2020

Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes

1 reference

12 December 2020

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

1 reference

12 December 2020

A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic).

1 reference

12 December 2020

Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function.

1 reference

12 December 2020

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

12 December 2020

Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications.

1 reference

12 December 2020

Imaging glutamate in schizophrenia: review of findings and implications for drug discovery

1 reference

12 December 2020

Amelioration of negative symptoms in schizophrenia by glycine.

1 reference

12 December 2020

Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?

1 reference

12 December 2020

Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action

1 reference

12 December 2020

Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study

1 reference

12 December 2020

The glutamatergic dysfunction hypothesis for schizophrenia

1 reference

12 December 2020

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

12 December 2020

Recent advances in the phencyclidine model of schizophrenia

1 reference

12 December 2020

The dopamine hypothesis of schizophrenia: version III--the final common pathway

1 reference

12 December 2020

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia

1 reference

12 December 2020

A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study

1 reference

12 December 2020

A multicenter, inpatient, phase 2, double-blind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia

1 reference

12 December 2020

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia

1 reference

12 December 2020

Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive

1 reference

12 December 2020

Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes

1 reference

12 December 2020

Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic

1 reference

12 December 2020

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

1 reference

12 December 2020

10.1007/S00213-016-4318-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27212398%20AND%20SRC:MED&resulttype=core&format=json

2 April 2020

1 reference